Castle Biosciences Inc. (CSTL) Reports Q4 EPS of $0.11

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of $0.11, versus $0.38 reported last year. Revenue for the quarter came in at $17.6 million, versus $11.44 million reported last year.

2020 Revenue Guidance:

Castle Biosciences anticipates generating $61-64 million in revenue in 2020.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c